{"filing":{"accession_number":"0001367644-26-000088","cik":"0001367644","ticker":"EBS","company_name":"Emergent BioSolutions Inc.","form":"8-K","filing_date":"2026-09-01","report_date":"2026-08-18","primary_document":"ebs-20260818.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1367644/000136764426000088/ebs-20260818.htm"},"events":[{"id":30968,"run_id":28399,"accession_number":"0001367644-26-000088","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Emergent received a $24 million contract modification from BARDA to supply additional doses of CYFENDUS® anthrax vaccine. This is a material government procurement contract award that represents a significant operational and revenue event for the company, but does not fit neatly into the specific financial categories (debt, dividend, impairment, etc.). The event is clearly operational—a material contract/procurement milestone—making operational_other the most appropriate classification.","company_name":"Emergent BioSolutions Inc.","ticker":"EBS","filing_date":"2026-09-01","form":"8-K","submitted_at":null,"items":[{"id":33733,"accession_number":"0001367644-26-000088","item_number":"8.01","item_title":"Other Events","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Emergent received a $24 million contract modification from BARDA to supply additional doses of CYFENDUS® anthrax vaccine. This is a material government procurement contract award that represents a significant operational and revenue event for the company, but does not fit neatly into the specific financial categories (debt, dividend, impairment, etc.). The event is clearly operational—a material contract/procurement milestone—making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T20:15:04.938669+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33733,"accession_number":"0001367644-26-000088","item_number":"8.01","item_title":"Other Events","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Emergent received a $24 million contract modification from BARDA to supply additional doses of CYFENDUS® anthrax vaccine. This is a material government procurement contract award that represents a significant operational and revenue event for the company, but does not fit neatly into the specific financial categories (debt, dividend, impairment, etc.). The event is clearly operational—a material contract/procurement milestone—making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T20:15:04.938669+00:00","company_name":"Emergent BioSolutions Inc.","ticker":"EBS","filing_date":"2026-09-01"}]}